1. Pink Sheet
  2. >>Geography
  3. >>Europe

Health Must Be At Center Of Post-Brexit Relationship, Say Industry & NHS Bodies

 
• By Ian Schofield

UK industry and National Health Service bodies say that the “political declaration” on the future UK-EU relationship fails to address key public health issues such as regulatory cooperation, collaboration in science and innovation, and tackling counterfeit medicines.

Relationship Management
Health must be central to the future UK-EU relationship, say industry & NHS • Source: Shutterstock

As prime minister Theresa May prepares to head to Brussels to discuss the future relationship between the UK and the EU after Brexit, a coalition of UK healthcare and life sciences organizations has called on both sides to ensure that public health matters are placed at the center of the negotiations.

The bare bones of the future relationship are currently sketched out in a short “political declaration” attached to the draft withdrawal agreement that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.